Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
The benefits of the drug outweigh a potential higher risk of bladder cancer and liver toxicity, an advisory panel to the Food and Drug Administration voted 13-1 today at a meeting in Silver Spring, Maryland. The FDA is expected to decide by Jan. 11 whether to approve the drug, known as dapagliflozin.
The FDA rejected the Type 2 diabetes drug in 2012 after a previous panel raised concern about the cancer risk. Research since found the drug may raise the risk of heart attack and stroke soon after starting treatment, though FDA staff said in a report Dec. 10 there is long-term cardiovascular benefit based on the ability to lower blood pressure and aid in weight loss.
http://www.businessweek.com/news/20...neca-diabetes-pill-wins-backing-of-advisers-1
The FDA rejected the Type 2 diabetes drug in 2012 after a previous panel raised concern about the cancer risk. Research since found the drug may raise the risk of heart attack and stroke soon after starting treatment, though FDA staff said in a report Dec. 10 there is long-term cardiovascular benefit based on the ability to lower blood pressure and aid in weight loss.
http://www.businessweek.com/news/20...neca-diabetes-pill-wins-backing-of-advisers-1